Table 2.
Comparison of background characteristics of patients who changed/continued or discontinued the treatment.
| Characteristics | Changed or Discontinued n = 18 (45.0%) |
Continued n = 22 (55.0%) |
p |
|---|---|---|---|
| Age (years old) | 80.2 (4.9) | 78.1 (4.7) | 0.169 |
| Gender (female) | 10 (55.6) | 16 (72.7) | 0.257 |
| BMI (kg/m2) | 18.8 (2.6) | 21.0 (4.1) | 0.097 |
| Patient With Smoking History | 7 (46.7) | 7 (36.8) | 0.563 |
| Patient With Habit of Alcohol | 4 (26.7) | 4 (18.2) | 0.916 |
| Comorbidities | |||
| Respiratory Disease | 10 (55.6) | 8 (36.4) | 0.225 |
| Malignancy | 5 (27.8) | 4 (18.2) | 0.705 |
| Impaired Immunity | 5 (27.8) | 2 (9.1) | 0.211 |
| Heart Disease | 6 (33.3) | 1 (4.6) | 0.033 |
| Patient With ADL Disability | 9 (50.0) | 3 (13.6) | 0.018 |
| Symptoms | |||
| Cough | 10 (55.6) | 13 (59.1) | 0.822 |
| Sputum | 9 (44.4) | 12 (54.6) | 0.525 |
| Hemoptysis | 3 (16.7) | 7 (31.8) | 0.465 |
| Dyspnea | 0 (0.0) | 2 (9.1) | 0.492 |
| Fever | 4 (22.2) | 1 (4.6) | 0.155 |
| Weight Loss | 3 (16.7) | 3 (13.) | 1.000 |
| Radiological Type | 0.641 | ||
| Fibrocavitary | 7 (38.9) | 7 (31.8) | |
| Nodular Bronchiectatic | 11 (61.1) | 15 (68.2) | |
| More Than Three Lobes Involved in CT | 11 (61.1) | 11 (50.0) | 0.482 |
| Diagnosed by Bronchofiberscopy | 4 (22.2) | 3 (13.6) | 0.680 |
| Prescribed Number of Antimycobacterial Drugs | 0.583 | ||
| Three or More Drugs | 13 (72.2) | 15 (68.2) | |
| Two Drugs | 2 (11.1) | 1 (4.6) | |
| Single Drug | 3 (16.7) | 6 (27.3) | |
| Standard Regimens * | 11 (61.1) | 13 (59.1) | 0.897 |
| Adverse Events Associated with Treatment | 11 (61.1) | 8 (36.4) | 0.203 |
Abbreviations: ADL = activities of daily living; AMK = amikacin; BMI = body mass index; CAM = clarithromycin; CT = computed tomography; EB = ethambutol; INH = isoniazid; IPM/CS = imipenem/cilastatin; RFP = rifampicin. Data are presented as n (%) for categorical data or mean values (standard deviation) for numeric data. * Standard regimens were defined as combination of RFP, EB, and CAM for M. avium complex, combination of INH, RFP, and EB for M. kansasii, and combination of AMK, CAM, and IPM/CS for M. abscessus.